Pancreatic cancer has the worst survival rates among all solid tumor types, and its incidence is increasing. Hypoxic conditions that arise from an imbalance between increased oxygen consumption and an inadequate oxygen supply play a key role in several solid tumors. This impacts the proliferation, migration, apoptosis and metabolism of tumor cells; hypoxia is considered a key contributor to chemoresistance in cancer cells.
Recent transcriptomic studies indicated a connection between neuroinflammation, changes in neuroimmune responses, and the development of autism spectrum disorder (ASD). The microglial calcium-binding protein A9 (S100A9) showed increased circulating levels in young adults, positively correlating with autistic severity.
The liver and pancreas are the main actors in glucose metabolism, but not the only ones. Muscles, adipose tissue and the brain play different roles. However, the prize for the best new actor in glucagon production goes to the innate lymphoid cells (ILCs), which, according to a study published in Science, respond to intestine neuron signals traveling to the pancreas to control glucose.
Researchers at Viva Star Biosciences (Suzhou) Co. Ltd. and Viva Star Biosciences (US) Inc. have described NLRP3 inflammasome inhibitors reported to be useful for the treatment of cryopyrin-associated periodic syndrome, multiple sclerosis, atherosclerosis, type 2 diabetes, osteoarthritis, cancer, Alzheimer’s disease and Parkinson’s disease.
Janssen Pharmaceutica NV has divulged mucosa associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors reported to be useful for the treatment of cancer.
Genescience Pharmaceuticals Co. Ltd. has synthesized cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.
Hangzhou Bio-Creativity Pharma-Tech Co. Ltd. has disclosed phosphatidylinositol 3-kinase γ (PI3Kγ) inhibitors reported to be useful for the treatment of atopic dermatitis.
Researchers from Guangzhou Medical University and affiliated organizations presented data from a study that aimed to investigate the disease-causing mechanism of EP400, a gene that encodes the E1A binding protein p400, which is a core catalytic ATPase subunit of ATP-dependent chromatin remodeling complexes.